Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer

Lung Cancer

Volumn 66, Issue 1, 2009, Pages 94-96

  Luciani, A ^a   Bertuzzi, C ^a   Ascione, G ^a   Di Gennaro, E ^a   Bozzoni, S ^a   Zonato, S ^a   Ferrari, D ^a   Foa, P ^a  

^a SAN PAOLO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Comorbidities; Dose intensity; Elderly; Non small cell lung cancer; Polypharmacy; Relative dose intensity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; NAVELBINE;

ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; GRANULOCYTOPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYPHARMACY; PRIORITY JOURNAL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68949211875     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.12.019     Document Type: Article

References (23)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
3. Wingo P., Cardinez C., and Landis S. Long term trends in cancer mortality in the United States. Cancer 97 Suppl. 12 (2003) 3133-3275
4. Yancik R., and Ries L.A. Cancer in older persons: an international issue in an aging world. Semin Oncol 31 (2004) 128-136
5. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 (2005) 3125-3137
6. Jatoi A., Hillman S., Stella P., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 9113-9119
7. Moscetti L., Nelli F., Padalino D., et al. Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother 17 (2005) 685-692
8. Lee D. Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status. Clin Lung Cancer 5 (2003) 86-89
9. Miller M.D., Paradis C.F., Houck P.R., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41 (1992) 237-248
10. Hryniuk W.M., and Goodyear M. The calculation of received dose intensity. J Clin Oncol 8 (1990) 1935-1937
11. Hryniuk W., and Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4 (1986) 1162-1170
12. Hryniuk W., and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (1984) 1281-1288
13. Skipper H. Data and analysis having to do with the influence of dose intensity and duration of treatment (single drugs and combination) on lethal toxicity and the therapeutic response of experimental neoplasm (1987), Southern Research Institute, Birmingam, AL [Booklets 13, 1986, and 2-13, 1987]
14. Crawford J. The importance of chemotherapy dose intensity in lung cancer. Semin Oncol 31 (2004) 25-31
15. Earle C.C., Tsai J.S., Gelber R.D., et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 19 (2001) 1064-1070
16. Langer C.J. Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 7 Suppl. 4 (2006) S126-137
17. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 (2003) 3201-3206
18. Gridelli C., Maione P., Illiano A., et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25 (2007) 4663-4669
19. Leo F., Scanagatta P., Baglio P., et al. The risk of pneumonectomy over the age of 70: a case-control study. Eur J Cardiothorac Surg 31 (2007) 779-782
20. Dominguez-Ventura A., Cassivi S.D., Allen M.S., et al. Lung cancer in octogenarians: factors affecting long-term survival following resection. Eur J Cardiothorac Surg 32 (2007) 370-374
21. Freeman M., Frankmann C., Beck J., and Valdivieso M. Prognostic nutrition factors in lung cancer patients. JPEN J Parenter Enteral Nutr 6 (1982) 122-127
22. Yovino S., Kwok Y., Krasna M., et al. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 62 (2005) 1438-1443
23. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 (2001) M146-156